Login to myESAIC Membership


The ESAIC is dedicated to supporting professionals in anaesthesiology and intensive care by serving as the hub for development and dissemination of valuable educational, scientific, research, and networking resources.



The ESAIC hosts the Euroanaesthesia and Focus Meeting congresses that serve as platforms for cutting-edge science and innovation in the field. These events bring together experts, foster networking, and facilitate knowledge exchange in anaesthesiology, intensive care, pain management, and perioperative medicine. Euroanaesthesia is one of the world’s largest and most influential scientific congresses for anaesthesia professionals. Held annually throughout Europe, our congress is a contemporary event geared towards education, knowledge exchange and innovation in anaesthesia, intensive care, pain and perioperative medicine, as well as a platform for immense international visibility for scientific research.


Professional Growth

The ESAIC's mission is to foster and provide exceptional training and educational opportunities. The ESAIC ensures the provision of robust and standardised examination and certification systems to support the professional development of anaesthesiologists and to ensure outstanding future doctors in the field of anaesthesiology and intensive care.



The ESAIC aims to advance patient outcomes and contribute to the progress of anaesthesiology and intensive care evidence-based practice through research. The ESAIC Clinical Trial Network (CTN), the Academic Contract Research Organisation (A-CRO), the Research Groups and Grants all contribute to the knowledge and clinical advances in the peri-operative setting.

Learn more about the ESAIC Clinical Trial Network (CTN) and the associated studies.


EU Projects

The ESAIC is actively involved as a consortium member in numerous EU funded projects. Together with healthcare leaders and practitioners, the ESAIC's involvement as an EU project partner is another way that it is improving patient outcomes and ensuring the best care for every patient.


Patient Safety

The ESAIC aims to promote the professional role of anaesthesiologists and intensive care physicians and enhance perioperative patient outcomes by focusing on quality of care and patient safety strategies. The Society is committed to implementing the Helsinki Declaration and leading patient safety projects.



To ESAIC is committed to implementing the Glasgow Declaration and drive initiatives towards greater environmental sustainability across anaesthesiology and intensive care in Europe.



The ESAIC works in collaboration with industry, national societies, and specialist societies to promote advancements in anaesthesia and intensive care. The Industry Partnership offers visibility and engagement opportunities for industry participants with ESAIC members, facilitating understanding of specific needs in anaesthesiology and in intensive care. This partnership provides resources for education and avenues for collaborative projects enhancing science, education, and patient safety. The Specialist Societies contribute to high-quality educational opportunities for European anaesthesiologists and intensivists, fostering discussion and sharing, while the National Societies, through NASC, maintain standards, promote events and courses, and facilitate connections. All partnerships collectively drive dialogue, learning, and growth in the anaesthesiology and intensive care sector.



Guidelines play a crucial role in delivering evidence-based recommendations to healthcare professionals. Within the fields of anaesthesia and intensive care, guidelines are instrumental in standardizing clinical practices and enhancing patient outcomes. For many years, the ESAIC has served as a pivotal platform for facilitating continuous advancements, improving care standards and harmonising clinical management practices across Europe.



With over 40 years of publication history, the EJA (European Journal of Anaesthesiology) has established itself as a highly respected and influential journal in its field. It covers a wide range of topics related to anaesthesiology and intensive care medicine, including perioperative medicine, pain management, critical care, resuscitation, and patient safety.



Becoming a member of ESAIC implies becoming a part of a vibrant community of nearly 8,000 professionals who exchange best practices and stay updated on the latest developments in anaesthesiology, intensive care and perioperative medicine. ESAIC membership equips you with the tools and resources necessary to enhance your daily professional routine, nurture your career growth, and play an active role in advancing anaesthesiology, intensive care and perioperative medicine.

Membership opportunities
at the ESAIC

Open Sidebar


The European Platform for Research Outcomes after PerIoperative Interventions in Surgery for Cancer Research Group (Euro-Periscope): The Onco-Anaesthesiology Research Group (RG)

Chair: Daniela Ionescu (Iuliu Hatieganu University of Medicine and Pharmacy, Cluj, Romania).

Vice-Chair: Oscar Cambronero Diaz (Hospital Universitari i Politècnic la Fe, Valencia, Spain).


This network emerged from EU-COST Action 15204 (2016-2021) of the same name, EURO-PERISCOPE. This was an EU-funded network of doctors, mainly but not exclusively anaesthesiologists and also surgeons, nurses and scientists, actively engaged in perioperative care of the cancer patient. It was Chaired and instigated by Donal Buggy (Mater University Hospital, Dublin, Ireland). It focused on the research question: ‘Can anaesthetic, analgesic or perioperative interventions during tumour resection surgery influence risk of recurrence?” This collaborative network involved >120 participants in 22 European and near neighbour nations. The activities of the EU COST Action were halted in the final year of its term due to the Coronavirus pandemic. ESAIC Euro-Periscope RG will take over where the EU network ended, at least for the anaesthesiologists and affiliated scientists.


The objectives of ESAIC Euro-Periscope RG are:

  1. To advocate that perioperative care of cancer patients is becoming increasingly common and specialised, meriting specific fellowship training and status as a recognised sub-specialty within anaesthesiology;
  2. To promote and lead research and quality improvement initiatives in perioperative management of cancer patients, focused not only on improving long term oncologic outcomes, but also on short term outcomes (e.g. QoR-15 scores, Days at Home at 30 days, reduced 30-day complications) that may also enhance longer term overall outcomes.
  3. To ensure a substantial European contribution to the definitive, global VAPOR-C RCT. This is led by Co-PIs Bernhard Riedel (Melbourne), Donal Buggy (Dublin) and Dan Sessler (Cleveland).
  4. To contribute to the ESA CTN observational study of colorectal cancer patients, ENCORE, led by Max Bell at the Karolinska Institut, Stockholm.

VAPOR- C Study design

VAPOR-C is an international multi-center, prospective randomized 2×2 factorial design trial with the aim to include almost 5,900 patients in total testing two hypotheses among patients undergoing surgery of curative intent with colorectal or non small cell lung tumours.

Primary Objectives

  1. Propofol TIVA increases Disease Free Survival compared with volatile sevoflurane anaesthesia;
  2. Lidocaine perioperatively (bolus + continuous infusion until discharged from PACU) increases Disease Free Survival compared with patients not receiving any lidocaine.

Secondary Objectives

To compare propofol-TIVA versus sevoflurane in regards to:

  • Days at Home at 30 days
  • Overall Survival
  • Post-operative complications
  • Functional capacity
  • Clinical frailty
  • Acute postoperative pain (postoperative day 1-3)

Inclusion criteria

  1. Male or female patients aged 18 years or older at screening
  2. Has provided written informed consent for the trial
  3. Patient with AJCC 8th edition Stage I-III colorectal cancer or Stage I-IIIa NSCLC, as confirmed by histological or cytological diagnosis.

Exclusion criteria

  1. Allergy to any of the anaesthetic drugs or techniques
  2. Known existing metastasis

Patients will be followed up every 6 months post-surgery until the close-out date.


A prospective observational study sponsored by ESAIC.

Aiming for 10,000 Stage I-III colorectal cancer patients undergoing surgery of curative intent.

Primary Objectives:

  1. To observe the effect of anaesthetic technique on:
  2. Short term: time to start of adjuvant chemotherapy in patients planned for RIOT
  3. Long term: Time to recurrence (TTR) at 2 years (± 1 month)

Secondary Objectives:

  1. 30-day postoperative morbidity
  2. Length of hospital stay and Days at home at 30 days (DAH-30)
  3. Adverse events related to oncological treatment (chemotherapy, radiotherapy)
  4. 1-year mortality

Inclusion Criteria:

  1. Age > 18 years
  2. ASA I-III
  3. Scheduled for elective (planned) colorectal cancer surgery for stage I-III (open or laparoscopic)
  4. Signed written informed consent when requested by the local Ethics committee

Exclusion Criteria:

  1. Uncontrolled renal or liver disease, restrictive (limiting mobility) heart failure or ischemic heart disease (ASA IV-V)
  2. Speech, language or cognitive difficulties precluding signing informed consent to participate
  3. Stage IV colo-rectal cancer